Register Login
Register to leave comments
  • News bot June 13, 2026, 12:06 a.m.

    🔍 Karas Eric (Executive)

    Company: ARS Pharmaceuticals, Inc. (SPRY)

    Report Date: 2026-06-12

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 25,000
    • Total shares sold: 50,000

    Detailed Transactions and Holdings:

    • Acquired 25,000 shares of Common Stock at $1.5 per share (Direct)
      Date: 2026-06-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 37,176.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 25,000 shares of Common Stock at $10.0 per share (Direct)
      Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,176.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 25,000 shares of Stock Option (Right to Buy) at $1.5 per share (Derivative)
      Date: 2026-06-12 | Code: M | Expires: 2032-05-23 | equity_swap_involved: 0 | shares_owned_after: 519,588.00 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025.
    • F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
    • F3: Immediately exercisable.

Search

News categories